Ginkgo Bioworks downgraded by William Blair
$DNA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
William Blair downgraded Ginkgo Bioworks from Mkt Perform to Underperform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/15/2024 | Neutral → Sell | BTIG Research | |
| 5/10/2024 | Mkt Perform → Underperform | William Blair | |
| 11/14/2023 | $3.50 → $2.50 | Outperform → Mkt Perform | Raymond James |
| 11/9/2023 | Buy → Neutral | BTIG Research | |
| 6/2/2023 | $3.00 → $1.25 | Neutral → Sell | Goldman |
| 5/11/2023 | Outperform → Mkt Perform | William Blair | |
| 11/29/2022 | $6.00 | Buy | Berenberg |
| 10/4/2022 | $5.00 | Equal-Weight | Morgan Stanley |
8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
144 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
144 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)